1. Home
  2. GETY vs ABUS Comparison

GETY vs ABUS Comparison

Compare GETY & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GETY
  • ABUS
  • Stock Information
  • Founded
  • GETY 1995
  • ABUS 2005
  • Country
  • GETY United States
  • ABUS United States
  • Employees
  • GETY N/A
  • ABUS N/A
  • Industry
  • GETY Industrial Machinery/Components
  • ABUS Biotechnology: Pharmaceutical Preparations
  • Sector
  • GETY Industrials
  • ABUS Health Care
  • Exchange
  • GETY Nasdaq
  • ABUS Nasdaq
  • Market Cap
  • GETY 701.0M
  • ABUS 611.0M
  • IPO Year
  • GETY N/A
  • ABUS N/A
  • Fundamental
  • Price
  • GETY $1.81
  • ABUS $3.37
  • Analyst Decision
  • GETY Hold
  • ABUS Strong Buy
  • Analyst Count
  • GETY 6
  • ABUS 3
  • Target Price
  • GETY $4.76
  • ABUS $5.67
  • AVG Volume (30 Days)
  • GETY 894.7K
  • ABUS 636.5K
  • Earning Date
  • GETY 08-11-2025
  • ABUS 08-06-2025
  • Dividend Yield
  • GETY N/A
  • ABUS N/A
  • EPS Growth
  • GETY N/A
  • ABUS N/A
  • EPS
  • GETY N/A
  • ABUS N/A
  • Revenue
  • GETY $946,828,000.00
  • ABUS $15,416,000.00
  • Revenue This Year
  • GETY $2.71
  • ABUS $3.35
  • Revenue Next Year
  • GETY $2.74
  • ABUS N/A
  • P/E Ratio
  • GETY N/A
  • ABUS N/A
  • Revenue Growth
  • GETY 4.43
  • ABUS 53.23
  • 52 Week Low
  • GETY $1.25
  • ABUS $2.71
  • 52 Week High
  • GETY $4.49
  • ABUS $4.73
  • Technical
  • Relative Strength Index (RSI)
  • GETY 52.11
  • ABUS 54.05
  • Support Level
  • GETY $1.55
  • ABUS $3.33
  • Resistance Level
  • GETY $1.88
  • ABUS $3.45
  • Average True Range (ATR)
  • GETY 0.11
  • ABUS 0.12
  • MACD
  • GETY 0.00
  • ABUS 0.01
  • Stochastic Oscillator
  • GETY 63.41
  • ABUS 36.21

About GETY Getty Images Holdings Inc.

Getty Images Holdings Inc. is a visual content creator and marketplace that offers a full range of content solutions. Through its Getty Images, Stock, and Unsplash brands, websites, and APIs, it serves customers around the world by allowing them to discover, purchase, and share visual content from photographers, illustrators, image partners, and videographers. The company generates a majority of its revenue through subscriptions, offering various subscription products on the Getty Images, iStock, and Unsplash websites. It operates and manages one operating segment, which is the business of developing and commercializing visual content. Geographically, the company generates maximum revenue from the Americas, followed by Europe, the Middle East and Africa, and the Asia-Pacific region.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: